Kenneth Pienta - Net Worth and Insider Trading

Kenneth Pienta Net Worth

The estimated net worth of Kenneth Pienta is at least $89,550 dollars as of 2024-04-29. Kenneth Pienta is the Director of Curis Inc and owns about 6,000 shares of Curis Inc (CRIS) stock worth over $86,820. Kenneth Pienta is also the Chief Medical Officer of Cue Biopharma Inc and owns about 2,000 shares of Cue Biopharma Inc (CUE) stock worth over $2,730. Details can be seen in Kenneth Pienta's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Kenneth Pienta has not made any transactions after 2021-03-16 and currently still holds the listed stock(s).

Transaction Summary of Kenneth Pienta

To

Kenneth Pienta Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Kenneth Pienta owns 2 companies in total, including Cue Biopharma Inc (CUE) , and Curis Inc (CRIS) .

Click here to see the complete history of Kenneth Pienta’s form 4 insider trades.

Insider Ownership Summary of Kenneth Pienta

Ticker Comapny Transaction Date Type of Owner
CUE Cue Biopharma Inc 2021-03-16 Chief Medical Officer
CRIS Curis Inc 2013-11-08 director

Kenneth Pienta Latest Holdings Summary

Kenneth Pienta currently owns a total of 2 stocks. Among these stocks, Kenneth Pienta owns 6,000 shares of Curis Inc (CRIS) as of November 8, 2013, with a value of $86,820 and a weighting of 96.95%. Kenneth Pienta also owns 2,000 shares of Cue Biopharma Inc (CUE) as of March 16, 2021, with a value of $2,730 and a weighting of 3.05%.

Latest Holdings of Kenneth Pienta

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
CRIS Curis Inc 2013-11-08 6,000 14.47 86,820
CUE Cue Biopharma Inc 2021-03-16 2,000 1.37 2,730

Holding Weightings of Kenneth Pienta


Kenneth Pienta Form 4 Trading Tracker

According to the SEC Form 4 filings, Kenneth Pienta has made a total of 0 transactions in Curis Inc (CRIS) over the past 5 years. The most-recent trade in Curis Inc is the acquisition of 4,000 shares on November 8, 2013, which cost Kenneth Pienta around $59,000.

According to the SEC Form 4 filings, Kenneth Pienta has made a total of 4 transactions in Cue Biopharma Inc (CUE) over the past 5 years, including 1 buys and 3 sells. The most-recent trade in Cue Biopharma Inc is the sale of 13,439 shares on March 16, 2021, which brought Kenneth Pienta around $202,929.

Insider Trading History of Kenneth Pienta

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Kenneth Pienta Trading Performance

GuruFocus tracks the stock performance after each of Kenneth Pienta's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Kenneth Pienta is -16.77%. GuruFocus also compares Kenneth Pienta's trading performance to market benchmark return within the same time period. The performance of stocks bought by Kenneth Pienta within 3 months outperforms 1 times out of 3 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Kenneth Pienta's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Kenneth Pienta

Average Return

-51.56%

Average return per transaction

Outperforming Transactions

0%

0 out of 3 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 6.92 -16.77 -27.54 -51.56 -26.82 -21.14
Relative Return to S&P 500(%) 5.33 -21.47 -36.41 -67.86 -33.12 -28.62

Kenneth Pienta Ownership Network

Ownership Network List of Kenneth Pienta

No Data

Ownership Network Relation of Kenneth Pienta


Kenneth Pienta Owned Company Details

What does Cue Biopharma Inc do?

Who are the key executives at Cue Biopharma Inc?

Kenneth Pienta is the Chief Medical Officer of Cue Biopharma Inc. Other key executives at Cue Biopharma Inc include President and CSO Anish Suri , director & CEO Daniel R Passeri , and Chief Medical Officer Matteo Levisetti .

Cue Biopharma Inc (CUE) Insider Trades Summary

Over the past 18 months, Kenneth Pienta made no insider transaction in Cue Biopharma Inc (CUE). Other recent insider transactions involving Cue Biopharma Inc (CUE) include a net sale of 9,325 shares made by Peter A Kiener , a net purchase of 4,000 shares made by Anish Suri , and a net purchase of 3,000 shares made by Daniel R Passeri .

In summary, during the past 3 months, insiders sold 0 shares of Cue Biopharma Inc (CUE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 9,325 shares of Cue Biopharma Inc (CUE) were sold and 7,000 shares were bought by its insiders, resulting in a net sale of 2,325 shares.

Cue Biopharma Inc (CUE)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Cue Biopharma Inc Insider Transactions

No Available Data

Kenneth Pienta Mailing Address

Above is the net worth, insider trading, and ownership report for Kenneth Pienta. You might contact Kenneth Pienta via mailing address: C/o Curis, Inc., 4 Maguire Road, Lexington Ma 02421.

Discussions on Kenneth Pienta

No discussions yet.